Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Breaking Barriers in Lung Cancer Research: The Intriguing Connection between IL-1β and PD-1/PD-L1 Pathways

Dan Ran Castillo
,
Won Jin Jeon
ORCID logo ,
Daniel Park
,
Bryan T. Pham
,
Chieh Yang
ORCID logo ,
Bowon Joung
,
Jin Hyun Moon
,
Jae Lee
,
Esther G. Chong
,
Kiwon Park
,
Mark E. Reeves
,
Penelope Duerksen-Hughes
,
Hamid Mirshahidi
,
Saied Mirshahidi
* ORCID logo
Version 1 : Received: 27 June 2023 / Approved: 27 June 2023 / Online: 27 June 2023 (07:16:09 CEST)

A peer-reviewed article of this Preprint also exists.

Castillo, D.R.; Jeon, W.J.; Park, D.; Pham, B.; Yang, C.; Joung, B.; Moon, J.H.; Lee, J.; Chong, E.G.; Park, K.; Reeves, M.E.; Duerksen-Hughes, P.; Mirshahidi, H.R.; Mirshahidi, S. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management. Int. J. Mol. Sci. 2023, 24, 11547. Castillo, D.R.; Jeon, W.J.; Park, D.; Pham, B.; Yang, C.; Joung, B.; Moon, J.H.; Lee, J.; Chong, E.G.; Park, K.; Reeves, M.E.; Duerksen-Hughes, P.; Mirshahidi, H.R.; Mirshahidi, S. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management. Int. J. Mol. Sci. 2023, 24, 11547.

Abstract

In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose a clinical challenge, as they may not respond to standard treatments like immune-checkpoint inhibitors (ICIs) and novel targeted therapies. While the mechanism of action of ICIs seems promising, the lack of a robust response limits their widespread use. Although the expression levels of programmed death ligand 1 (PD-L1) on tumor cells are used to predict ICI response, identifying new biomarkers, particularly those associated with the tumor microenvironment (TME), is crucial to address this unmet need. Recently, inflammatory cytokines such as interleukin-1 beta (IL-1β) have emerged as a key area of focus and hold significant potential implications for future clinical practice. Combinatorial approaches of IL-1β inhibitors and ICIs may provide a potential therapeutic modality for NSCLC patients without targetable mutations. In this review, we discuss the role of IL-1β in NSCLC, its involvement in inflammatory pathways, and explore its potential role in the treatment of NSCLC.

Keywords

interleukin-1 beta (IL-1β); immune-checkpoint inhibitors (ICIs); non-small cell lung cancer (NSCLC); programmed death ligand 1 (PD-L1); therapeutic resistance

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.